Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 5/2023

27.11.2022 | Maternal-fetal Medicine

Fetal pancreas size and maternal serum biomarkers glycated albumin and insulin-regulated aminopeptidase provide no potential for early prediction of gestational diabetes mellitus

verfasst von: Filiz Yarsilikal Guleroglu, Aliye Balkan Ozmen, Isil Turan Bakirci, Sevilay Yavuz Dogu, Ibrahim Yılmaz, Ali Cetin

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aimed to determine the predictive values of fetal pancreas size and maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP) for gestational diabetes mellitus (GDM).

Materials and methods

In this prospective observational study including 109 pregnant women, the fetal pancreas size and maternal serum biomarkers GA and IRAP were measured at the gestational age of 20–22 weeks and later at the gestational age of 24–28 weeks, in 19 participants of them, GDM was confirmed with the 75-g oral glucose tolerance test (OGTT) and the fetal pancreas size was measured in all the participants again.

Results

The median fetal pancreas sizes were significantly higher in women with or without GDM when measured at the 24–28 weeks of pregnancy compared to those at the 20–22 weeks of pregnancy (p < 0.05). At both of the 20–22 and 24–28 weeks of pregnancy, the median values of fetal pancreas sizes in the women with or without GDM were found comparable (p > 0.05). There were no significant differences between pregnant women with or without GDM regarding maternal serum biomarkers GA and IRAP (p > 0.05). Multivariate logistic regression analysis revealed no meaningful association of study parameters with the development of GDM.

Conclusion

The fetal pancreas size and maternal serum biomarkers GA and IRAP provide no potential for early prediction of GDM at the 20–22 weeks of gestation. Further studies, including serial measurement of these parameters during the second and third trimesters of GDM pregnancies, may clarify their role in the antenatal care of women with GDM.

Clinical trials

NCT05392231.
Literatur
2.
Zurück zum Zitat Shou C, Wei Y-M, Wang C, Yang H-X (2019) Updates in long-term maternal and fetal adverse effects of gestational diabetes mellitus. Matern Fetal Med 1:91–94 CrossRef Shou C, Wei Y-M, Wang C, Yang H-X (2019) Updates in long-term maternal and fetal adverse effects of gestational diabetes mellitus. Matern Fetal Med 1:91–94 CrossRef
14.
Zurück zum Zitat Kansu-Celik H, Ozgu-Erdinc AS, Kisa B, Findik RB, Yilmaz C, Tasci Y (2019) Prediction of gestational diabetes mellitus in the first trimester: comparison of maternal fetuin-A, N-terminal proatrial natriuretic peptide, high-sensitivity C-reactive protein, and fasting glucose levels. Arch Endocrinol Metab 63:121–127. https://doi.org/10.20945/2359-3997000000126CrossRefPubMed Kansu-Celik H, Ozgu-Erdinc AS, Kisa B, Findik RB, Yilmaz C, Tasci Y (2019) Prediction of gestational diabetes mellitus in the first trimester: comparison of maternal fetuin-A, N-terminal proatrial natriuretic peptide, high-sensitivity C-reactive protein, and fasting glucose levels. Arch Endocrinol Metab 63:121–127. https://​doi.​org/​10.​20945/​2359-3997000000126CrossRefPubMed
15.
Zurück zum Zitat Hattan RA, Rees GK, Johnson ML (1982) Normal fetal anatomy. Radiol Clin North Am 20:271–284PubMed Hattan RA, Rees GK, Johnson ML (1982) Normal fetal anatomy. Radiol Clin North Am 20:271–284PubMed
16.
Zurück zum Zitat Cyr DR (1983) Ultrasonic visualization of the fetal pancreas and hepatic venous circulation. Med Ultrasound 7:27–31 Cyr DR (1983) Ultrasonic visualization of the fetal pancreas and hepatic venous circulation. Med Ultrasound 7:27–31
24.
30.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet (London, England) 352:837–853CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet (London, England) 352:837–853CrossRef
37.
Zurück zum Zitat Krskova K, Balazova L, Dobrocsyova V, Olszanecki R, Suski M, Chai SY et al (2020) Insulin-regulated aminopeptidase inhibition ameliorates metabolism in obese zucker rats. Front Mol Biosci 7:586225CrossRefPubMedPubMedCentral Krskova K, Balazova L, Dobrocsyova V, Olszanecki R, Suski M, Chai SY et al (2020) Insulin-regulated aminopeptidase inhibition ameliorates metabolism in obese zucker rats. Front Mol Biosci 7:586225CrossRefPubMedPubMedCentral
Metadaten
Titel
Fetal pancreas size and maternal serum biomarkers glycated albumin and insulin-regulated aminopeptidase provide no potential for early prediction of gestational diabetes mellitus
verfasst von
Filiz Yarsilikal Guleroglu
Aliye Balkan Ozmen
Isil Turan Bakirci
Sevilay Yavuz Dogu
Ibrahim Yılmaz
Ali Cetin
Publikationsdatum
27.11.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2023
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-022-06860-2

Weitere Artikel der Ausgabe 5/2023

Archives of Gynecology and Obstetrics 5/2023 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Menopausale Hormontherapie für Frauen über 65?

07.05.2024 Klimakterium und Menopause Nachrichten

In den USA erhalten nicht wenige Frauen auch noch im Alter über 65 eine menopausale Hormontherapie. Welche positiven und negativen gesundheitlichen Konsequenzen daraus möglicherweise resultieren, wurde anhand von Versicherungsdaten analysiert.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.